Specify Company / Ticker to Get the Summary
Dividend History CTXR
Dividend Analytics CTXR
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Citius Pharmaceuticals Inc
CTXRCitius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Address: 11 Commerce Drive, Cranford, NJ, United States, 07016
Analytics
WallStreet Target Price
6.00 USDP/E Ratio
–Dividend Yield
–Financials CTXR
Results | 2019 | Dynamics |